Fresenius Medical Care stock reports 23 percent operating growth

Published on 10/04/2026 at 11:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fresenius Medical Care posted EUR 569 million in adjusted Q2 operating income on August 3, 2026. Q3 results are scheduled for November 3, 2026, while Goldman Sachs cut its target to EUR 38.

Modernes Klinik-Atrium mit Glasdach, hellem Eingangsbereich und Pflanzen — Ein helles, weitläufiges Klinik-Atrium mit Glasdach und modernem Eingangsbereich – architektonisch vergleichbar mit den Dialysezentren und Gesundheitseinrichtungen von Fresenius Medical Care AG (ISIN DE0005785802) weltweit, Illustration mit AI erstellt.

Fresenius Medical Care stock (ISIN DE0005785802) closed at EUR 39.550 on Xetra on October 2, 2026, down 0.33 percent from the prior close of EUR 39.680. The company enters its next reporting phase after Q2 operating income excluding special items rose 23 percent to EUR 569 million on August 3, 2026, according to The Globe and Mail.

Q2 growth sets the benchmark

Fresenius Medical Care reported Q2 2026 revenue of EUR 4.861 billion, up 4 percent at constant currency and slightly above consensus. The company also reaffirmed its financial outlook for 2026, making the November update the next test for whether operating improvement is broadening beyond the latest quarter.

The comparison is especially relevant because adjusted operating income grew faster than revenue. That spread points to operating leverage, although the figures exclude special items and currency effects, so the quality of the improvement will matter as much as the headline growth rate.

Analysts trim expectations

On September 30, 2026, Goldman Sachs cut its FMC price target from EUR 39 to EUR 38 and maintained a Neutral rating, citing limited treatment-volume growth in its outlook for the November report, as wallstreetONLINE reported.

The broader analyst picture is more balanced. Investing.com lists a Neutral consensus from 17 analysts, with 3 Buy, 8 Hold and 6 Sell ratings. Its average 12-month target is EUR 41.685, which is 5.40 percent above the Xetra closing price, with estimates ranging from EUR 30 to EUR 67.

China costs meet a lower price

FMC is also reshaping its China business by ending production and sales of the 4008A hemodialysis system and its peritoneal dialysis business there. The September 25, 2026 announcement includes a EUR 110 million one-time cost estimate for the third quarter, while the company plans to emphasize newer dialysis technologies and intensive-care products, according to Die Zeit.

Stock stays below its yearly high

At EUR 39.550, FMC stock was 17.3 percent below its 52-week high of EUR 47.860 and 14.4 percent above its 52-week low of EUR 34.570 on October 2, 2026. Market capitalization stood at EUR 10.5 billion, with 504,420 shares traded.